SECUKINUMAB SHOWS HIGHER SYMPTOMATIC IMPROVEMENT VERSUS ETANERCEPT IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 24 WEEKS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON

被引：0

作者：

Mease, P. ^{[1
,2
]}

Choy, E. ^{[3
]}

Thom, H. ^{[4
]}

Kalyvas, C. ^{[5
]}

Lopes, N. ^{[6
]}

Pricop, L. ^{[7
]}

Gandhi, K. ^{[7
]}

Jugl, S. M. ^{[8
]}

Nash, P. ^{[9
]}

机构：

[1] Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Seattle, WA USA

[3] Cardiff Univ, Cardiff, S Glam, Wales

[4] Univ Bristol, Bristol, Avon, England

[5] Mapi Grp, Houten, Netherlands

[6] Novartis Biociencias SA, Sao Paulo, Brazil

[7] Novartis Pharmaceut, E Hanover, NJ USA

[8] Novartis Pharma AG, Basel, Switzerland

[9] Univ Queensland, Brisbane, Qld, Australia

来源：

关键词：

D O I：

10.1016/j.jval.2017.08.2961

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PMS6

引用

页码：A936 / A936

页数：1